This pharmacoepidemiology study examines associations between first-trimester antipsychotic exposure and risk for overall congenital and cardiac malformations among children born to women enrolled in Medicaid.
This randomized clinical trial compares the effects of adjunctive raloxifene with antipsychotic therapy vs antipsychotics alone on illness severity in women with refractory schizophrenia.
This systematic review and meta-analysis assesses type 2 diabetes mellitus risk associated with antipsychotic treatment in youth.
This network meta-analysis assesses the efficacy of all antipsychotics used in patients with treatment-resistant schizophrenia.
This Editorial discusses the use of antipsychotic medications for indications other than psychosis in young people who do not have psychosis.
This case-control study examines whether mortality increases in elderly patients with dementia who receive antipsychotic medications.
This case-control cross-sectional study finds that short-term treatment with antipsychotics was associated with prefrontal cortical thinning, but that treatment was associated with better cognitive control and increased prefrontal functional activity.
This prospective controlled study reports that corticostriatal functional dysconnectivity in psychosis is a state-dependent phenomenon. Increased functional connectivity of the striatum with prefrontal and limbic regions may be a biomarker for improvement in symptoms associated with antipsychotic treatment.
This meta-analysis of 6 placebo-controlled studies examines whether the baseline severity of schizophrenia influences the efficacy of antipsychotic drugs.
This study assesses cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders.
Umbricht and colleagues aimed to determine the efficacy and safety of bitopertin, a glycine reuptake inhibitor, in patients with schizophrenia and predominant negative symptoms who were stable while taking an antipsychotic treatment. Goff provided a related editorial.
Lane and coauthors examine the clinical and cognitive efficacy and safety of add-on treatment of sodium benzoate for schizophrenia.
In a retrospective cohort study, Bobo and coauthors compare the risk of type 2 diabetes in children and youth 6 to 24 years of age for recent initiators of antipsychotic drugs vs propensity score–matched controls who had recently another psychotropic medication.
Wunderink et al conduct a long-term follow-up evaluation of a randomized clinical trial comparing maintenance treatment with dose reduction/discontinuation of antipsychotic drugs in patients with remitted first-episode psychosis. McGorry et al provide an editorial.